BioCentury | May 12, 2014
Clinical News

Nimotuzumab: Phase III discontinued

...the U.S. and Europe to treat glioma. InnoMab Pte. Ltd., a JV between CIMAB and InnoKeys...
...pediatric and adult glioma. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CIMAB S.A. , Havana, Cuba InnoKeys...
BioCentury | Dec 10, 2012
Company News

InnoKeys, YM BioSciences deal

...YM's CIMYM BioSciences Inc. subsidiary sold its assets related to nimotuzumab to InnoKeys for $2 million...
...in North America, Europe, Japan, Korea, Australia and other countries. According to YM, CIMAB and InnoKeys...
...gained the compound through its 2010 acquisition of Cytopia Ltd. (see BioCentury, Feb. 8, 2010). InnoKeys Pte. Ltd....
Items per page:
1 - 2 of 2
BioCentury | May 12, 2014
Clinical News

Nimotuzumab: Phase III discontinued

...the U.S. and Europe to treat glioma. InnoMab Pte. Ltd., a JV between CIMAB and InnoKeys...
...pediatric and adult glioma. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India CIMAB S.A. , Havana, Cuba InnoKeys...
BioCentury | Dec 10, 2012
Company News

InnoKeys, YM BioSciences deal

...YM's CIMYM BioSciences Inc. subsidiary sold its assets related to nimotuzumab to InnoKeys for $2 million...
...in North America, Europe, Japan, Korea, Australia and other countries. According to YM, CIMAB and InnoKeys...
...gained the compound through its 2010 acquisition of Cytopia Ltd. (see BioCentury, Feb. 8, 2010). InnoKeys Pte. Ltd....
Items per page:
1 - 2 of 2